Idenix Pharmaceuticals News
Idenix Pharmaceuticals Inc. (IDIX) reported a loss of 21 cents per share in the fourth quarter of 2013, wider than the year ago loss of 17 cents per share but narrower than the Zacks Consensus Estimate loss of 22 cents.
IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anYahoo 02/27 18:42 ET
CAMBRIDGE, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human ...
CAMBRIDGE, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present at the Cowen & Company 34th Annual Health Care Conference ...
The No. 1 stock on this list has more than half its float short.
Jay R. Luly, Ph.D., President, Chief Executive Officer and Director of Enanta Pharmaceuticals, Inc. (ENTA), Expects "Strong, Competitive Data Set in All-Oral Therapy for HCV Genotype 1"Yahoo 02/20 10:10 ET
It is not too late to join the biotech bandwagon.
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.